Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following Bunionectomy

ClinicalTrials.gov ID: NCT05324358

Public ClinicalTrials.gov record NCT05324358. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Active and Placebo-Controlled Trial to Evaluate the Analgesic Efficacy and Safety of NTM-001 for the Treatment of Moderately Severe Postoperative Pain Following Bunionectomy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This clinical study is a randomized, double-blind, double-dummy, parallel group, multi-center, active and placebo-controlled trial evaluating the analgesic efficacy and safety of NTM-001 in subjects with moderately severe postoperative pain after bunionectomy surgery. This study is designed to compare the efficacy of NTM-001 to placebo. Intravenous (IV) morphine serves as an active comparator to determine assay sensitivity and support assessment of opioid-level analgesia for NTM-001. Effectiveness, safety, and tolerability parameters will be descriptively compared between treatment arms.

Study identification

NCT ID: NCT05324358
Recruitment status: Suspended
Study type: Interventional
Phase: Phase 3
Lead sponsor: Neumentum, Inc.; Other
Enrollment: 341 participants

Conditions and interventions

Conditions

Pain, Postoperative

Interventions

Drug · Other

Eligibility (public fields only)

Age range: 18 Years to 64 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 14, 2022 (Actual)
Primary completion: Sep 6, 2024 (Actual)
Completion: May 2027 (Estimated)
Last update posted: Apr 23, 2026

2022 – 2027

United States locations

U.S. sites: 10
U.S. states: 8
U.S. cities: 10

Facility	City	State	ZIP	Site status
Sun City Clinical Research	Sun City	Arizona	85351	—
Trovare Clinical Research	Bakersfield	California	93301	—
Alliance Research Intitute	Canoga Park	California	91304	—
Pasadena Clinical Trials	Pomona	California	91767	—
Dr. Vince Clinical Research	Overland Park	Kansas	66212	—
Chesapeake Research	Pasadena	Maryland	21122	—
Curalta Clinical Trials	Westwood	New Jersey	07675	—
Midwest Clinical Research Center	Dayton	Ohio	45417	—
The Orthopedic Center	Tulsa	Oklahoma	74104	—
Endeavor Clinical Trials	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05324358, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 23, 2026 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05324358 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →